Research programme: diabetic retinopathy/neuropathy therapy - Scotia Holdings

Drug Profile

Research programme: diabetic retinopathy/neuropathy therapy - Scotia Holdings

Latest Information Update: 22 Jan 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QuantaNova Canada [CEASED]; Scotia Holdings [CEASED]
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies; Diabetic retinopathy

Most Recent Events

  • 22 Jan 2002 Discontinued-Preclinical for Diabetic neuropathies in Canada (Unknown route)
  • 22 Jan 2002 Discontinued-Preclinical for Diabetic retinopathy in United Kingdom (Unknown route)
  • 27 Jun 2000 QuantaNova Canada, the genomics-based discovery unit of Scotia, is investigating a therapeutic target for diabetic neuropathies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top